NASDAQ$CUE
Cue Biopharma Inc · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
Cue Biopharma reported fourth quarter and full year 2019 financial results.
Cue Biopharma reported collaboration revenue of $1.0 million for the fourth quarter of 2019, and cash and cash equivalents of $59.4 million as of December 31, 2019. The company focused on clinical development of CUE-101 and made progress on its Immuno-STAT™ Platform.
- Extended cash runway with $33.3 million from at-the-market equity offerings in Q4 2019.
- Focused on clinical development of CUE-101 as a Phase 1 monotherapy dose escalation and expansion trial in HNSCC.
- Immuno-STAT™ Platform for autoimmune disease featured in Merck presentation at the Antigen-Specific Immune Tolerance Drug Development Summit.
- Published paper on preclinical and translational data supporting the therapeutic potential of CUE-101 in HPV16-related malignancies in peer-reviewed journal Clinical Cancer Research
Headline financials
Revenue & EPS history
Cue Biopharma · Revenue · Quarterly
$1.05M
Revenue by segment
Cue Biopharma · $1.05M total across 1 segment · Q4 2019
- Collaboration revenue$1.05M—100.0%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2019
-0.1%
Avg return
Earnings day
-1.2%
Avg return
5 days after
+1.3%
Avg return
30 days after
45%
15 / 33 earnings
Positive
+25.2%
Q4 2021
Best reaction
-16.7%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -14.2% | -31.0% | — | |
| Q4 2025 | -0.3% | -14.7% | +97.1% | |
| Q3 2025 | -8.5% | -13.2% | -27.1% | |
| Q2 2025 | +0.0% | +3.7% | -6.1% | |
| Q1 2025 | -3.5% | -2.5% | -18.6% | |
| Q4 2024 | +3.3% | -2.4% | -9.4% | |
| Q3 2024 | -16.7% | -28.0% | -37.3% | |
| Q2 2024 | -6.3% | +19.9% | -7.1% | |
| Q1 2024 | -8.9% | -18.8% | -22.5% | |
| Q4 2023 | +2.7% | -5.4% | +3.2% | |
| Q3 2023 | +14.9% | +5.4% | +8.1% | |
| Q2 2023 | -12.3% | -14.2% | -26.5% | |
| Q1 2023 | -3.7% | -12.4% | -23.2% | |
| Q4 2022 | +7.1% | +7.4% | +14.2% | |
| Q3 2022 | +20.4% | +2.5% | -6.1% | |
| Q2 2022 | +1.7% | -5.7% | +3.3% | |
| Q1 2022 | -11.0% | -10.0% | -8.5% | |
| Q4 2021 | +25.2% | +27.2% | +2.9% | |
| Q3 2021 | -0.4% | +6.4% | +4.1% | |
| Q2 2021 | +7.7% | +3.5% | +23.1% | |
| Q1 2021 | -1.4% | +2.4% | -4.2% | |
| Q4 2020 | -7.5% | -4.5% | -14.3% | |
| Q3 2020 | +11.2% | +7.1% | +17.3% | |
| Q2 2020 | +1.3% | +2.5% | -16.0% | |
| Q1 2020 | +8.3% | +13.3% | -4.4% | |
| Q4 2019 | -15.5% | +4.8% | +59.8% | |
| Q3 2019 | -2.0% | -1.8% | +38.4% | |
| Q2 2019 | +1.3% | +7.5% | +6.4% | |
| Q1 2019 | +0.1% | +1.5% | -6.7% | |
| Q4 2018 | +9.7% | +23.8% | +20.3% | |
| Q3 2018 | -6.7% | -8.8% | -16.2% | |
| Q2 2018 | -0.7% | -4.9% | +11.3% | |
| Q4 2017 | +0.5% | +1.2% | -13.5% | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro